135 related articles for article (PubMed ID: 15650940)
1. Oncology business development global summit.
Bockman JM; Nalam S
IDrugs; 2005 Jan; 8(1):37-40. PubMed ID: 15650940
[No Abstract] [Full Text] [Related]
2. Repurposing Drugs in Oncology: Next Steps.
Verbaanderd C; Meheus L; Huys I; Pantziarka P
Trends Cancer; 2017 Aug; 3(8):543-546. PubMed ID: 28780930
[TBL] [Abstract][Full Text] [Related]
3. Keynote comment: Cancer drug pricing in the USA.
Johnson DH
Lancet Oncol; 2006 Jun; 7(6):444-5. PubMed ID: 16750490
[No Abstract] [Full Text] [Related]
4. Deal-making trends in oncology.
Moore K; Walker J
Nat Rev Drug Discov; 2009 Aug; 8(8):604. PubMed ID: 19644466
[No Abstract] [Full Text] [Related]
5. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
American Society of Clinical Oncology
J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
[No Abstract] [Full Text] [Related]
6. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
7. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
Beatty PA; Laking GR
J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
[No Abstract] [Full Text] [Related]
8. Innovative oncology products: time to revisit the strategy development?
Krendyukov A
ESMO Open; 2019; 4(5):e000571. PubMed ID: 31749992
[No Abstract] [Full Text] [Related]
9. Robbing Peter to pay Paul? Financial reimbursement for chemotherapy.
Arceci RJ
J Pediatr Hematol Oncol; 2003 Apr; 25(4):277-8. PubMed ID: 12679638
[No Abstract] [Full Text] [Related]
10. Cancer Therapy: Shooting for the Moon.
Lee J; Blumenthal GM; Hohl RJ; Huang SM
Clin Pharmacol Ther; 2017 May; 101(5):552-558. PubMed ID: 28418166
[No Abstract] [Full Text] [Related]
11. Payer management of oncology gets serious.
Snyder M; Goldberg L; Ryan T
Am J Manag Care; 2012 Feb; 18(1 Spec No.):SP6-7. PubMed ID: 22468875
[No Abstract] [Full Text] [Related]
12. An audience with...Joseph Bolen. Interview by Bethan Hughes.
Bolen J
Nat Rev Drug Discov; 2009 Aug; 8(8):608. PubMed ID: 19644470
[TBL] [Abstract][Full Text] [Related]
13. Industry, clinical trials, and the cost of cancer drugs: an investor's perspective.
Fiorino T
J Clin Oncol; 2007 Jul; 25(19):e21-3. PubMed ID: 17602065
[No Abstract] [Full Text] [Related]
14. Molecular imaging: what picture does it paint for future oncology?
Price P; Jones T
Drug Discov Today; 2002 Jul; 7(14):741-3. PubMed ID: 12547021
[No Abstract] [Full Text] [Related]
15. Discontinued drugs in 2010: oncology drugs.
Williams R
Expert Opin Investig Drugs; 2011 Nov; 20(11):1479-96. PubMed ID: 21955127
[TBL] [Abstract][Full Text] [Related]
16. 27th Annual JPMorgan Healthcare Conference--Antisoma and Keryx Biopharmaceuticals.
Croasdell G; Gale S
IDrugs; 2009 Mar; 12(3):152-4. PubMed ID: 19333892
[No Abstract] [Full Text] [Related]
17. Reforming the payment system for medical oncology.
Bach PB
JAMA; 2013 Jul; 310(3):261-2. PubMed ID: 23817729
[No Abstract] [Full Text] [Related]
18. Novel approaches to delivering value in oncology drugs.
Miller S
Clin Adv Hematol Oncol; 2016 Apr; 14(4):244-6. PubMed ID: 27166606
[No Abstract] [Full Text] [Related]
19. Biomedicine. Pharma firms push for sharing of cancer trial data.
Bhattacharjee Y
Science; 2012 Oct; 338(6103):29. PubMed ID: 23042862
[No Abstract] [Full Text] [Related]
20. Pharmaceutical downsizing and oncology drug development.
Senior K
Lancet Oncol; 2008 Jan; 9(1):11. PubMed ID: 18183658
[No Abstract] [Full Text] [Related]
[Next] [New Search]
